Defendant Name: Becton, Dickinson and Company

Defendant Type: Public Company

Document Reference: 2024-201

Document Details

Legal Case Name In the Matter of Becton, Dickinson and Company
Document Name Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump; New Jersey-Based Company Will Also Retain Independent Compliance Consultant
Document Date 16-Dec-2024
Document Format Administrative Proceeding
File Number 3-22361
Allegation Type Issuer Reporting and Disclosure
Document Summary On December 16, 2024, the SEC "today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer known as BD, for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump. BD agreed to pay a $175 million civil penalty."

Disgorgement & Penalty Information

Resolutions
Cease and Desist Order
Compliance Related Independent Consultant
Monetary Penalties:

Civil Penalty

Individual:     $175,000,000.00 Shared:    

Related Documents:

33-11344 16-Dec-2024 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On December 16, 2025, the SEC instituted settled cease-and-desist proceedings against Becton, Dickinson and Company, stating: "This matter involves Becton Dickinson’s repeated misrepresentations to investors regarding the risks it was taking in selling one of its most important products. From 2016 to early 2020, BD understood its Alaris infusion pump, whose sales contributed about 10% of BD’s profits, required new regulatory clearance from the FDA to address historical changes to the device and to fix multiple software flaws that posed safety risks to patients. BD misrepresented these risks and failed to disclose the risk that the FDA would prohibit sales of Alaris until the company obtained new clearance and fixed its software. BD also overstated its income by failing to properly account for the costs of fixing the device."
34-102395 11-Feb-2025 Administrative Proceeding
Extension Order
The Commission ordered that: "the Division’s request for an extension of time until February 20, 2026, to submit a Proposed Plan of Distribution is granted."